BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two investigational studies evaluating the combination of REVLIMID® (lenalidomide) plus rituximab in indolent non-Hodgkin’s lymphoma (NHL) were presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL.
